Acadia Pharmaceuticals (ACAD) Net Margin (2010 - 2026)

Acadia Pharmaceuticals' Net Margin history runs 17 years deep, the most recent figure standing at 1.36% for Q1 2026.

• In Q1 2026, Net Margin fell 641.0% year-over-year to 1.36%; the TTM figure through Mar 2026 stood at 34.3% (up 1132.0% YoY), while the FY2025 annual figure was 36.49%, up 1285.0% from the prior year.
• Net Margin for Q1 2026 stood at 1.36%, down from 96.33% in the prior quarter.
• The five-year high for Net Margin was 96.33% in Q4 2025, with the low at 97.91% in Q1 2022.
• The 5-year median for Net Margin is 7.77% (2025), against an average of 0.62%.
• The sharpest annual moves came in 2022 and 2023: Net Margin tumbled 3555 bps in 2022, then soared 6159 bps in 2023.
• Acadia Pharmaceuticals' Net Margin stood at 30.51% in 2022, then surged by 165 bps to 19.82% in 2023, then surged by 179 bps to 55.37% in 2024, then surged by 74 bps to 96.33% in 2025, then tumbled by 99 bps to 1.36% in 2026.
• Business Quant data shows ACAD's Net Margin at 1.36% in Q1 2026, 96.33% in Q4 2025, and 25.76% in Q3 2025.